세계의 면역조직화학염색(IHC) 시장 : 제품별, 용도별 - 예측(-2029년)

Immunohistochemistry (IHC) Market by Product (Antibodies (Type, Clonality), Reagents, Equipment, Kits, Software), Application (Diagnostics (Cancer, Infectious, Autoimmune, Neurological), Research (Drug Development), Forensic) - Global Forecast to 2029

US $ 4,950 ￦ 7,096,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,534,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,684,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,337,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

면역조직화학염색(IHC) 시장 규모는 2024년 37억 달러에서 예측 기간 동안 7.2%의 CAGR(연평균 성장률)을 기록하며 2029년에는 52억 달러 규모로 성장할 것으로 예상됩니다.

시장 성장을 견인하는 요인은 고령 인구의 암 환자 유병률 증가와 암 진단 및 관리를 위한 IHC 검사의 적용이 증가하고 있기 때문입니다. 또한, 동반진단(CDx) 개발 및 개인 맞춤형 의료 개발을 위한 IHC 기술과의 융합은 시장 확대를 더욱 촉진하고 있습니다. 환자 예후를 개선하기 위한 약물 개발 및 질병 관리 지원에 IHC를 적용하고, 제약회사와 학술기관 간 진행 중인 공동 연구도 시장 진입자들에게 성장 기회를 제공하고 있습니다.

조사 범위
조사 대상 연도	2022-2029년
기준 연도	2023년
예측 기간	2022-2029년
단위	금액(달러)
부문	제품, 용도, 최종사용자, 지역
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

"시약 중 조직 염색 부문이 가장 큰 점유율을 차지할 것으로 예상"

조직 염색 부문은 2023년 시약 하위 부문 중 가장 큰 점유율을 보였으며, IHC에서 조직 염색은 조직 샘플의 특정 세포 성분과 구조를 시각화하고 구별하는 데 사용됩니다. 조직 염색은 다중 염색이라고도 합니다. 이 방법은 하나의 조직 절편에서 여러 표적을 검출하기 위해 여러 개의 염색을 사용합니다. 다중 염색 외에도 조직 염색은 정상 조직과 비정상 조직의 형태를 구별하여 암을 진단하는 데에도 사용됩니다. 이러한 용도는 IHC 시장을 주도하는 주요 요인입니다.

"용도별로는 연구용 부문이 두 번째 점유율을 차지"

연구용은 2023년 두 번째 점유율을 차지했습니다. 연구에서 IHC 기술은 항종양제 개발 및 바이오마커 탐색에 사용됩니다. 특정 단백질의 발현과 세포 내 위치를 파악하여 암 및 기타 질병을 연구하는 데 도움이 될 수 있습니다. 예를 들어, IHC는 암 단백질체 연구에 널리 사용되어 새로운 신약 개발 타겟을 발견하는 데 도움이 되고 있습니다. 연구에 사용되는 자동 IHC 플랫폼은 슬라이드 간 일관된 염색을 제공하여 신뢰할 수 있는 결과를 얻기 위해 필수적이며, IHC 기술은 발생학 연구와 같은 발생학 연구에서도 중요하며, 배아 발생 단계에서 주요 단백질을 시각화하는 데 도움이 됩니다. 줄기세포 연구에서 IHC는 분화 및 증식 마커를 모니터링하여 줄기세포의 행동에 대한 인사이트를 제공합니다. 또한, 약물 검사에서 IHC는 조직 내 특정 단백질 발현에 대한 신약의 효과를 평가하는 데 도움이 됩니다. 이러한 용도는 IHC가 과학 연구를 촉진하고 다양한 질병에 대한 이해와 치료를 개선하는 데 중요한 역할을 하고 있음을 강조합니다.

"아시아태평양이 가장 빠르게 성장하는 지역으로"

아시아태평양은 예측 기간 동안 가장 높은 CARG를 보일 것으로 예상됩니다. 이 지역의 높은 성장률은 연구 및 임상 응용 분야에서 첨단 IHC 제품(예: 분석 및 진단 키트 등)의 빠른 채택에 기인합니다. 이 외에도 고령 인구의 증가, 연구 활동에 대한 투자 및 자금 조달 증가, 가처분 소득 증가, 학술 및 의료 인프라 개발 등이 이 지역의 높은 성장률을 이끄는 주요 요인으로 작용하고 있습니다.

세계 면역조직화학염색(IHC) 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 기술·특허 동향, 규제 환경, 시장 규모 추정 및 예측, 각종 부문별·지역별 상세 분석, 경쟁 환경, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 고객의 비즈니스에 영향을 미치는 동향/디스럽션
• 가격 분석
• 기술 분석
• 특허 분석
• 밸류체인 분석
• 공급망 분석
• 생태계 분석
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• 규제 상황
• 주요 회의와 이벤트
• 투자와 자금 조달 시나리오
• AI/생성형 AI가 면역조직화학 시장에 미치는 영향

제6장 면역조직화학염색(IHC) 시장 : 제공별

• 항체
  • 유형별
  • 1차 항체
  • 2차 항체
  • 복제성별
  • 단클론항체
  • 다클론항체
• 시약
  • 조직 염색
  • 블로킹 혈청과 시약
  • 발색성 기질
  • 고정 시약
  • 희석제
  • 유기용제
  • 단백질 분해 효소
  • 기타
• 장비
  • 슬라이드 염색 시스템
  • 조직 처리 시스템
  • 슬라이드 스캐너
  • 기타
• 키트
  • 인간 면역조직화학 키트
  • 동물 면역조직화학 키트
• 소프트웨어

제7장 면역조직화학염색(IHC) 시장 : 용도별

• 진단
  • 암
  • 감염증
  • 신장질환
  • 자가면역질환
  • 신경질환
  • 기타
• 연구
  • 의약품 개발·시험
  • 기타
• 법의학

제8장 면역조직화학염색(IHC) 시장 : 최종사용자별

• 병원·진단 실험실
• 학술연구기관·CRO
• 기타

제9장 면역조직화학염색(IHC) 시장 : 지역별

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제10장 경쟁 상황

• 주요 기업의 전략/유력 기업
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 기업
• 기업 평가 매트릭스 : 스타트업/중소기업
• 기업 가치 평가와 재무 지표
• 브랜드/제품 비교
• 경쟁 시나리오

제11장 기업 개요

• 주요 기업
  • F. HOFFMANN-LA ROCHE LTD.
  • DANAHER CORPORATION
  • AGILENT TECHNOLOGIES, INC.
  • PHC HOLDINGS CORPORATION
  • THERMO FISHER SCIENTIFIC INC.
  • MERCK KGAA
  • BIO-RAD LABORATORIES, INC.
  • BIO-TECHNE
  • BECTON, DICKINSON AND COMPANY
  • TAKARA BIO INC.
  • ENZO BIOCHEM INC.
  • SINO BIOLOGICAL, INC.
  • SAKURA FINETEK JAPAN CO., LTD.
  • CELL SIGNALING TECHNOLOGY, INC.
  • BIO SB
  • MILTENYI BIOTEC
  • ORIGENE TECHNOLOGIES, INC.
• 기타 기업
  • EAGLEBIO
  • BIOCARE MEDICAL, LLC
  • ELABSCIENCE BIONOVATION INC.
  • BIOGENEX
  • DIAGNOSTIC BIOSYSTEMS INC.
  • HISTO-LINE LABORATORIES
  • ROCKLAND IMMUNOCHEMICALS, INC.
  • CANDOR BIOSCIENCE GMBH
  • GENEMED BIOTECHNOLOGIES, INC.

제12장 부록

ksm

영문 목차

영문목차

The global immunohistochemistry market is projected to reach USD 5.2 billion by 2029 from USD 3.7 billion in 2024, at a CAGR of 7.2% during the forecast period of 2024 to 2029. Factors propelling the growth of the market are the increased prevalence of cancer cases among the growing geriatric population and the rising application of IHC tests for the diagnosis and management of cancer. Moreover, the development of companion diagnostics (CDx) and its integration with IHC technology for the development of personalized medicine further support the expansion of the market. Application of IHC in supporting drug development and disease management to improve patient outcomes, along with ongoing research collaboration between pharmaceutical companies and academic institutes provide growth opportunities for players in the Immunohistochemistry Market.

Scope of the Report
Years Considered for the Study	2022-2029
Base Year	2023
Forecast Period	2022-2029
Units Considered	Value (USD Billion)
Segments	Product, Application, End User, and Region
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

"Histological Stain is expected to account for the largest share of by reagents segment."

In 2023, the histological stains market accounted for the largest share of the reagent subsegment within the product segment. In immunohistochemistry, histological stains are used to visualize and differentiate specific cellular components and structures within tissue samples. Histological stains are also used in multiplex staining also known as multiple staining. In this technique, more than one stains are used to detect multiple targets within a single tissue section. Apart from multiplex staining, histological stains are also used for cancer diagnosis by distinguishing normal and abnormal tissue morphology. These applications are major factors that drive the market for histological stains

"Research applications segment accounted for the second-largest share of the application segment."

In 2023, research applications accounted for the second-largest share of the application segment of the IHC market. In research, IHC technology is used for anti-tumor drug development and biomarker discovery. It helps researchers to identify the expression of specific proteins and their locations within cells, aiding in the study of cancer and other diseases. For example, IHC is widely used to study the cancer proteome, which helps in finding new drug targets. Automated IHC platforms used in research offer consistent staining across slides, which is essential for reliable results. IHC techniques are also important in developmental studies, like embryological research, where they help visualize key proteins during the embryonic development phase. In stem cell research, IHC is used to monitor differentiation and proliferation markers, providing insights into stem cell behavior. Additionally, in drug testing, IHC helps evaluate the effects of new drugs on specific protein expressions within tissues. These applications highlight the important role of IHC in advancing scientific research and improving the understanding and treatment of various diseases.

"Asia Pacific is the fastest-growing region in the immunohistochemistry market."

The immunohistochemistry market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM), the Middle East, and Africa. Asia Pacific is the fastest-growing region in terms of CARG during the forecast period. The high growth rate of the region can be attributed to the fast adoption of the latest technologies such as advanced IHC products (like assays and diagnostic kits) in research and clinical applications. This factor, coupled with the increasing geriatric population, rising investments and funding for research activities, increasing disposable income, and developing academic and healthcare infrastructures in the region are key drivers for the high growth rate of the region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 55%, CXOs - 20%, and Executives - 25%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, Latin America- 7%, Middle East and Africa-3%

Prominent Players in the Immunohistochemistry market are F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US).

Research Coverage:

This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunohistochemistry market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Rising Geriatric Population and Increasing Cancer Prevalence, Innovations and advancements in Immunohistochemistry (IHC) Technology, Reimbursement Coverage for Immunohistochemistry (IHC) Tests, Rising Adoption of Digital Pathology), restraint (Adoption of alternative technologies and a high degree of consolidation), opportunities (Rising demand for personalized medicine, Growing adoption of companion diagnostics, Growth opportunities in emerging countries, Integration of artificial intelligence in IHC), Challenges (Stringent regulatory requirements, Lack of Standardization)
• Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the Immunohistochemistry market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the Immunohistochemistry market across varied regions.
• Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Immunohistochemistry market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffman-La Roche Ltd (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US) among others in the Immunohistochemistry market. The report also helps stakeholders understand the pulse of the IHC market and provides them with information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS AND EXCLUSIONS
• 1.4 STUDY SCOPE
  • 1.4.1 SEGMENTS COVERED
  • 1.4.2 YEARS CONSIDERED
  • 1.4.3 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 RESEARCH DESIGN
  • 2.1.2 SECONDARY DATA
    • 2.1.2.1 Secondary data sources
    • 2.1.2.2 Objectives of secondary research
  • 2.1.3 PRIMARY DATA
    • 2.1.3.1 Objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 REVENUE SHARE ANALYSIS (TOP-DOWN APPROACH)
  • 2.2.2 INSIGHTS FROM PRIMARIES
• 2.3 MARKET GROWTH FORECAST
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW
• 4.2 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION AND COUNTRY (2023)
• 4.3 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
• 4.4 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2023
• 4.5 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of cancer and rising geriatric population
    • 5.2.1.2 Technological innovations and advancements in immunohistochemistry diagnostics
    • 5.2.1.3 Favorable reimbursement coverage for immunohistochemistry tests
    • 5.2.1.4 Growing focus on digital pathology
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Adoption of alternative technologies in molecular diagnostics and research
    • 5.2.2.2 Highly consolidated market
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing demand for precision/personalized medicines
    • 5.2.3.2 Increasing adoption of companion diagnostics
    • 5.2.3.3 Growth opportunities in emerging economies
    • 5.2.3.4 Integration of AI in immunohistochemistry
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory requirements for tissue diagnostic instruments and consumables
    • 5.2.4.2 Lack of standardization
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE OF IMMUNOHISTOCHEMISTRY PRODUCTS, 2023
  • 5.4.2 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021-2023
  • 5.4.3 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2021-2023
• 5.5 TECHNOLOGY ANALYSIS
  • 5.5.1 KEY TECHNOLOGIES
    • 5.5.1.1 Automated immunohistochemistry systems
    • 5.5.1.2 Multiplex immunohistochemistry
  • 5.5.2 COMPLEMENTARY TECHNOLOGIES
    • 5.5.2.1 Chromogenic detection
    • 5.5.2.2 Fluorescent detection
  • 5.5.3 ADJACENT TECHNOLOGIES
    • 5.5.3.1 In situ hybridization
• 5.6 PATENT ANALYSIS
  • 5.6.1 METHODOLOGY
  • 5.6.2 INNOVATION AND PATENT APPLICATIONS
  • 5.6.3 TOP PATENT APPLICANTS
• 5.7 VALUE CHAIN ANALYSIS
  • 5.7.1 RESEARCH & DEVELOPMENT
  • 5.7.2 MANUFACTURING
  • 5.7.3 LOGISTICS AND POST-SALES
• 5.8 SUPPLY CHAIN ANALYSIS
• 5.9 ECOSYSTEM ANALYSIS
  • 5.9.1 ROLE OF RAW MATERIAL SUPPLIERS
  • 5.9.2 ROLE OF PRODUCT PROVIDERS
  • 5.9.3 ROLE OF END USERS
  • 5.9.4 ROLE OF REGULATORY AUTHORITIES
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10.2 BARGAINING POWER OF SUPPLIERS
  • 5.10.3 BARGAINING POWER OF BUYERS
  • 5.10.4 THREAT OF SUBSTITUTES
  • 5.10.5 THREAT OF NEW ENTRANTS
• 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.11.2 KEY BUYING CRITERIA
• 5.12 REGULATORY LANDSCAPE
  • 5.12.1 REGULATORY ANALYSIS
    • 5.12.1.1 North America
      • 5.12.1.1.1 US
      • 5.12.1.1.2 Canada
    • 5.12.1.2 Europe
    • 5.12.1.3 Asia Pacific
      • 5.12.1.3.1 Japan
      • 5.12.1.3.2 China
      • 5.12.1.3.3 India
    • 5.12.1.4 Latin America
      • 5.12.1.4.1 Brazil
• 5.13 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.14 INVESTMENT AND FUNDING SCENARIO
• 5.15 IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET

6 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 ANTIBODIES
  • 6.2.1 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE
  • 6.2.2 PRIMARY ANTIBODIES
    • 6.2.2.1 Increasing adoption of targeted immunotherapy to drive segment
  • 6.2.3 SECONDARY ANTIBODIES
    • 6.2.3.1 Better signal amplification and easier manufacturing process to fuel segment growth
  • 6.2.4 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY
  • 6.2.5 MONOCLONAL ANTIBODIES
    • 6.2.5.1 Increased applications in cancer diagnostics to support market growth
  • 6.2.6 POLYCLONAL ANTIBODIES
    • 6.2.6.1 Better sensitivity and higher resistant to changes in antigen conformation to augment segment growth
• 6.3 REAGENTS
  • 6.3.1 HISTOLOGICAL STAINS
    • 6.3.1.1 Growing focus on cancer diagnostics and developmental research to drive segment
  • 6.3.2 BLOCKING SERA AND REAGENTS
    • 6.3.2.1 Need to prevent non-specific binding and provide accurate outcomes to drive adoption
  • 6.3.3 CHROMOGENIC SUBSTRATES
    • 6.3.3.1 Rapid detection and faster diagnosis to propel segment growth
  • 6.3.4 FIXATION REAGENTS
    • 6.3.4.1 Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption
  • 6.3.5 DILUENTS
    • 6.3.5.1 Focus on reducing non-specific background staining during immunostaining to aid segment growth
  • 6.3.6 ORGANIC SOLVENTS
    • 6.3.6.1 Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market
  • 6.3.7 PROTEOLYTIC ENZYMES
    • 6.3.7.1 Proteolytic enzymes to improve accessibility of target antibodies
  • 6.3.8 OTHER REAGENTS
• 6.4 EQUIPMENT
  • 6.4.1 SLIDE-STAINING SYSTEMS
    • 6.4.1.1 Availability of technologically advanced slide-staining systems to fuel segment growth
  • 6.4.2 TISSUE PROCESSING SYSTEMS
    • 6.4.2.1 High equipment cost and need for extensive regulatory compliance to limit market
  • 6.4.3 SLIDE SCANNERS
    • 6.4.3.1 Accurate insights into complexity of tissue interactions and multi-parameter cellular expressions to aid adoption
  • 6.4.4 OTHER EQUIPMENT
• 6.5 KITS
  • 6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS
    • 6.5.1.1 Increasing focus on cancer research to fuel segment growth
  • 6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS
    • 6.5.2.1 Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth
• 6.6 SOFTWARE
  • 6.6.1 GROWING FOCUS ON DIGITAL PATHOLOGY FOR MORE ACCURATE DIAGNOSIS TO DRIVE MARKET

7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 DIAGNOSTIC APPLICATIONS
  • 7.2.1 CANCER
    • 7.2.1.1 Increasing target population and rising adoption of targeted therapies to propel market growth
  • 7.2.2 INFECTIOUS DISEASES
    • 7.2.2.1 High prevalence of infectious diseases and need for early diagnosis to aid market growth
  • 7.2.3 NEPHROLOGICAL DISEASES
    • 7.2.3.1 Rising prevalence of renal transplant-associated conditions to drive market
  • 7.2.4 AUTOIMMUNE DISEASES
    • 7.2.4.1 Focus on differentiating autoimmune diseases from similar clinical presentations to augment market growth
  • 7.2.5 NEUROLOGICAL DISEASES
    • 7.2.5.1 Increasing global burden of neurological disorders to spur market growth
  • 7.2.6 OTHER DISEASES
• 7.3 RESEARCH APPLICATIONS
  • 7.3.1 DRUG DEVELOPMENT AND TESTING
    • 7.3.1.1 Need for accurate and objective outcomes in drug testing to augment segment growth
  • 7.3.2 OTHER RESEARCH APPLICATIONS
• 7.4 FORENSIC APPLICATIONS
  • 7.4.1 INCREASED DEMAND FOR EFFECTIVE DETERMINATION OF PATHOLOGICAL CHANGES TO SUPPORT MARKET GROWTH

8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
  • 8.2.1 LOW COST OF SPECIALTY DIAGNOSTIC TESTS AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH
• 8.3 ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS
  • 8.3.1 GROWING APPLICATION OF IMMUNOHISTOCHEMISTRY TESTS FOR DRUG DEVELOPMENT TO POSITIVELY IMPACT MARKET GROWTH
• 8.4 OTHER END USERS

9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 US to dominate North American immunohistochemistry market during forecast period
  • 9.2.3 CANADA
    • 9.2.3.1 High incidence of cancer and increased demand for advanced diagnostics to propel market growth
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 High investments in life science R&D and favorable reimbursement policies to drive market
  • 9.3.3 UK
    • 9.3.3.1 Rising prevalence of cancer and increasing government funding in health research to augment market growth
  • 9.3.4 FRANCE
    • 9.3.4.1 Increased research in cancer diagnosis and treatment to support market growth
  • 9.3.5 ITALY
    • 9.3.5.1 Advanced health infrastructure and high geriatric population to fuel market growth
  • 9.3.6 SPAIN
    • 9.3.6.1 Increased demand for personalized medicines to boost adoption of immunohistochemistry products
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 Increasing focus on advanced cancer diagnostics to spur market growth
  • 9.4.3 JAPAN
    • 9.4.3.1 High geriatric population and increased government healthcare expenditure to support market growth
  • 9.4.4 INDIA
    • 9.4.4.1 Need for high-end pathology and diagnostic services to propel market growth
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Increased patient population and high demand for quality healthcare to aid market growth
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Focus on precision healthcare and personalized medicines to drive market
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Increasing research initiatives and rising cancer cases to drive market
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Saudi Arabia
      • 9.6.2.1.1 Growing cancer burden and increasing focus on research to augment market growth
    • 9.6.2.2 UAE
      • 9.6.2.2.1 Favorable government initiatives and high investments in healthcare infrastructure to fuel market growth
    • 9.6.2.3 Rest of GCC Countries
  • 9.6.3 REST OF MIDDLE EAST
• 9.7 AFRICA
  • 9.7.1 RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET
  • 9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET
• 10.3 REVENUE ANALYSIS, 2021-2023
• 10.4 MARKET SHARE ANALYSIS, 2023
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Offering footprint
    • 10.5.5.3 Application footprint
    • 10.5.5.4 Region footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 10.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS
  • 10.9.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 F. HOFFMANN-LA ROCHE LTD.
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products/Solutions offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product launches and approvals
      • 11.1.1.3.2 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 DANAHER CORPORATION
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products/Solutions offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches and approvals
      • 11.1.2.3.2 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses and competitive threats
  • 11.1.3 AGILENT TECHNOLOGIES, INC.
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products/Solutions offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches and approvals
      • 11.1.3.3.2 Deals
      • 11.1.3.3.3 Expansions
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 PHC HOLDINGS CORPORATION
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products/Solutions offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Deals
      • 11.1.4.3.2 Other developments
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses and competitive threats
  • 11.1.5 THERMO FISHER SCIENTIFIC INC.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products/Solutions offered
  • 11.1.6 MERCK KGAA
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products/Solutions offered
  • 11.1.7 BIO-RAD LABORATORIES, INC.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products/Solutions offered
  • 11.1.8 BIO-TECHNE
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products/Solutions offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Deals
      • 11.1.8.3.2 Expansions
      • 11.1.8.3.3 Other developments
  • 11.1.9 BECTON, DICKINSON AND COMPANY
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products/Solutions offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Expansions
  • 11.1.10 TAKARA BIO INC.
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products/Solutions offered
  • 11.1.11 ENZO BIOCHEM INC.
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products/Solutions offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Expansions
  • 11.1.12 SINO BIOLOGICAL, INC.
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products/Solutions offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Expansions
  • 11.1.13 SAKURA FINETEK JAPAN CO., LTD.
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products/Solutions offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product launches
      • 11.1.13.3.2 Deals
  • 11.1.14 CELL SIGNALING TECHNOLOGY, INC.
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products/Solutions offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Deals
  • 11.1.15 BIO SB
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products/Solutions offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Product launches
  • 11.1.16 MILTENYI BIOTEC
    • 11.1.16.1 Business overview
    • 11.1.16.2 Products/Solutions offered
  • 11.1.17 ORIGENE TECHNOLOGIES, INC.
    • 11.1.17.1 Business overview
    • 11.1.17.2 Products/Solutions offered
• 11.2 OTHER PLAYERS
  • 11.2.1 EAGLEBIO
  • 11.2.2 BIOCARE MEDICAL, LLC
  • 11.2.3 ELABSCIENCE BIONOVATION INC.
  • 11.2.4 BIOGENEX
  • 11.2.5 DIAGNOSTIC BIOSYSTEMS INC.
  • 11.2.6 HISTO-LINE LABORATORIES
  • 11.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
  • 11.2.8 CANDOR BIOSCIENCE GMBH
  • 11.2.9 GENEMED BIOTECHNOLOGIES, INC.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS

관련자료